Drug Profile
Research programme: asparagine depletion anticancer therapeutics - DevaCell
Alternative Names: SHELSparLatest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator DevaCell
- Class Amidohydrolases; Enzymes
- Mechanism of Action Asparagine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia; Lymphoma
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Leukaemia in USA (IM)
- 28 Sep 2020 No recent reports of development identified for research development in Leukaemia in USA (IV)
- 28 Sep 2020 No recent reports of development identified for research development in Lymphoma in USA (IM)